Score:
10.5/15
Analyze what earned this score 🔥
Topper’s Copy
GS3
Indian Polity
15 marks
“Recent advances in HIV treatment have focused on targeting the viral capsid using long-acting drugs such as lenacapavir.”
Explain the significance of capsid-targeting therapies in controlling HIV infection. Also discuss the challenges of drug resistance and the role of combination therapy.
Student’s Answer
Evaluation by SuperKalam
Demand of the Question
- Explain the significance of capsid-targeting therapies in controlling HIV infection
- Discuss the challenges of drug resistance specific to these therapies
- Discuss the role of combination therapy in HIV treatment
What you wrote:
Recent breakthroughs in Antiretroviral Therapy (ART) have shifted from targeting viral enzymes to the HIV-1 Capsid - the protein shell protecting the virus genetic material. The most important prominent advancement is Lenacapavir, the world's first capsid-based inhibitor approved for multi-drug resistant (MDR) HIV-1 infection.
Recent breakthroughs in Antiretroviral Therapy (ART) have shifted from targeting viral enzymes to the HIV-1 Capsid - the protein shell protecting the virus genetic material. The most important prominent advancement is Lenacapavir, the world's first capsid-based inhibitor approved for multi-drug resistant (MDR) HIV-1 infection.
Suggestions to improve:
- Could briefly define what the HIV capsid is in simpler terms (e.g., "the cone-shaped protein shell that houses viral RNA and enzymes") before diving into lenacapavir to enhance clarity for broader understanding.
What you wrote:
[DRAWING: A flowchart explaining the significance of capsid targeting.
The central box is labeled "Significance of Capsid-Targeting (Lenacapavir)".
An arrow points from a box above it which reads "Multistage inhibition-capsid inhibitors disrupt the viral life cycle at multiple steps, & include uncoating, nuclear entry, and viral assembly."
An arrow points to the left to a box labeled "Long-Acting Profile", with text below it reading "Lenacapavir's unique pharmacokinetic properties allow for subcutaneous injections once every six months".
An arrow points down to a box labeled "High Barrier to Resistance", with text below it reading "The HIV Capsid is genetically fragile, mutations required to escape the drug often damage the virus's own fitness, making it a weaker resistant strain, to thrive".]
[DRAWING: A flowchart explaining the significance of capsid targeting.
The central box is labeled "Significance of Capsid-Targeting (Lenacapavir)".
An arrow points from a box above it which reads "Multistage inhibition-capsid inhibitors disrupt the viral life cycle at multiple steps, & include uncoating, nuclear entry, and viral assembly."
An arrow points to the left to a box labeled "Long-Acting Profile", with text below it reading "Lenacapavir's unique pharmacokinetic properties allow for subcutaneous injections once every six months".
An arrow points down to a box labeled "High Barrier to Resistance", with text below it reading "The HIV Capsid is genetically fragile, mutations required to escape the drug often damage the virus's own fitness, making it a weaker resistant strain, to thrive".]
Suggestions to improve:
- Can explain the mechanism more clearly (e.g., "Capsid inhibitors prevent the uncoating process necessary for reverse transcription, thereby stopping viral replication before DNA integration into host cells").
- Could mention pre-exposure prophylaxis (PrEP) potential of lenacapavir (e.g., "Recent trials show lenacapavir reduces HIV acquisition by 99.9% when used as injectable PrEP, offering protection beyond treatment").
What you wrote:
[DRAWING: A flowchart explaining the challenges of drug resistance.
The central box is labeled "Challenges of Drug Resistance".
An arrow points to the left to a box labeled "Target Mutations", with text below it reading "Q661, Q67H can reduce drug binding affinity, leading to treatment failure, especially during mono therapy."
An arrow points to the center-bottom to a box labeled "Selective pressure & suboptimal drug levels", with text below it reading "Levels dip/subside to missed doses or the 'longtail' of injectable drugs - can create selective pressure that favors the emergence of resistant variants."
An arrow points to the right to a box labeled "Pre-existing Resistance", with text below it reading "In highly treatment experienced patients, pre-existing resistance to other drug classes necessitates complex regimen.".]
[DRAWING: A flowchart explaining the challenges of drug resistance.
The central box is labeled "Challenges of Drug Resistance".
An arrow points to the left to a box labeled "Target Mutations", with text below it reading "Q661, Q67H can reduce drug binding affinity, leading to treatment failure, especially during mono therapy."
An arrow points to the center-bottom to a box labeled "Selective pressure & suboptimal drug levels", with text below it reading "Levels dip/subside to missed doses or the 'longtail' of injectable drugs - can create selective pressure that favors the emergence of resistant variants."
An arrow points to the right to a box labeled "Pre-existing Resistance", with text below it reading "In highly treatment experienced patients, pre-existing resistance to other drug classes necessitates complex regimen.".]
Suggestions to improve:
- Can add cross-resistance concerns (e.g., "Unlike NRTI resistance that affects multiple drugs in the same class, capsid mutations are unique, making lenacapavir valuable when combined with drugs targeting reverse transcriptase or integrase").
- Could mention adherence challenges with long-acting injectables (e.g., "While six-month dosing improves compliance, delayed resistance detection between doses poses monitoring challenges").
What you wrote:
Role of Combination Therapy
1) Synergistic suppression: Using Lenacapavir in combination with other drug classes that interfere with the virus creates multiple obstacles to replication, simultaneously reducing the probability of the virus developing simultaneous resistance mutations.
2) Maintaining viral suppression: Combination therapy ensures the viral load remains undetectable which prevents further mutation and stops the transmission of virus.
3) Strategic Deployments for MDR patients: Lenacapavir acts as a salvage therapy, providing a new mechanism of action when all other options have failed.
Role of Combination Therapy
1) Synergistic suppression: Using Lenacapavir in combination with other drug classes that interfere with the virus creates multiple obstacles to replication, simultaneously reducing the probability of the virus developing simultaneous resistance mutations.
2) Maintaining viral suppression: Combination therapy ensures the viral load remains undetectable which prevents further mutation and stops the transmission of virus.
3) Strategic Deployments for MDR patients: Lenacapavir acts as a salvage therapy, providing a new mechanism of action when all other options have failed.
Suggestions to improve:
- Can provide specific combination examples (e.g., "Lenacapavir + bictegravir (integrase inhibitor) + emtricitabine (NRTI) creates a triple-barrier regimen where virus must develop three independent mutations simultaneously").
- Could mention treatment-as-prevention (TasP) concept (e.g., "Combination therapy achieving undetectable viral loads ensures U=U principle—undetectable equals untransmittable—critical for epidemic control").
What you wrote:
Conclusion:
Capsid targeting therapies like Lenacapavir represent a "paradigm shift" in HIV management, moving toward a vaccine-like preventive and therapeutic model. For India, where generic manufacturers have secured royalty-free licenses to produce Lenacapavir at low cost, this technology is critical for achieving the UNAIDS 95-95-95 targets by 2030.
Conclusion:
Capsid targeting therapies like Lenacapavir represent a "paradigm shift" in HIV management, moving toward a vaccine-like preventive and therapeutic model. For India, where generic manufacturers have secured royalty-free licenses to produce Lenacapavir at low cost, this technology is critical for achieving the UNAIDS 95-95-95 targets by 2030.
Suggestions to improve:
- Could briefly mention the need for strengthening healthcare infrastructure (e.g., "However, realizing this potential requires strengthening cold-chain logistics for injectable storage and training healthcare workers for subcutaneous administration in resource-limited settings").
Your answer demonstrates strong technical knowledge with specific details like mutation types and pharmacokinetic properties. The flowcharts enhance presentation effectively. However, the answer could better integrate the three demands—particularly linking resistance challenges explicitly to why combination therapy is essential. Strengthening these connections with concrete examples would elevate the response significantly.
Demand of the Question
- Explain the significance of capsid-targeting therapies in controlling HIV infection
- Discuss the challenges of drug resistance specific to these therapies
- Discuss the role of combination therapy in HIV treatment
What you wrote:
Recent breakthroughs in Antiretroviral Therapy (ART) have shifted from targeting viral enzymes to the HIV-1 Capsid - the protein shell protecting the virus genetic material. The most important prominent advancement is Lenacapavir, the world's first capsid-based inhibitor approved for multi-drug resistant (MDR) HIV-1 infection.
Recent breakthroughs in Antiretroviral Therapy (ART) have shifted from targeting viral enzymes to the HIV-1 Capsid - the protein shell protecting the virus genetic material. The most important prominent advancement is Lenacapavir, the world's first capsid-based inhibitor approved for multi-drug resistant (MDR) HIV-1 infection.
Suggestions to improve:
- Could briefly define what the HIV capsid is in simpler terms (e.g., "the cone-shaped protein shell that houses viral RNA and enzymes") before diving into lenacapavir to enhance clarity for broader understanding.
More Challenges
View All- View Challenge
GS2
Indian Polity
Yesterday
The balance between transparency and privacy is a recurring constitutional challenge in India.
In the light of recent amendments to the RTI framework through the Digital Personal Data Protection law, examine whether the exemption of personal information undermines accountability of public authorities. - View Challenge
GS2
Indian Polity
26 Feb, 2026
“Changing the name of a State in India reflects the cooperative yet asymmetrical nature of Indian federalism.”
Discuss the constitutional procedure for renaming a State and examine the role played by the State Legislature and Parliament in this process. - View Challenge
GS3
Economy
25 Feb, 2026
“Asset monetisation has emerged as a critical pillar of India’s infrastructure financing strategy.”
In this context, critically examine the objectives, mechanisms and challenges of the National Monetisation Pipeline 2.0 (NMP 2.0). How can it contribute to sustainable infrastructure development while safeguarding public interest?
